SCHEMBL570061

SCHEMBL570061

Cn1nc(C(=O)O)cc1-c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ RPA1 P27694 5/20 0.63
▸ ALDH1A1 P00352 2/20 0.60
▸ GRM5 P41594 1/20 0.57
▸ MAPT P10636 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ MEN1 O00255 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ KDM4E B2RXH2 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ MME P08473 1/20 0.51
▸ PLA2G10 O15496 1/20 0.50
▸ MARS1 P56192 1/20 0.49
▸ BCL2 P10415 2/20 0.48
▸ MDM2 Q00987 2/20 0.48
▸ MCL1 Q07820 2/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ PPP1CA P62136 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17324771 0.88 GRM5 (0.56) RPA1ALDH1A1GRM5MAPTHTT
SCHEMBL20656279 0.86 RPA1 (0.47) RPA1ALDH1A1GRM5MAPTHTT
SCHEMBL167558 0.86 GRM5 (0.58) RPA1ALDH1A1GRM5MAPTHTT
SCHEMBL2565035 0.85 RPA1 (0.66) RPA1GRM5MEN1KMT2AL3MBTL1
SCHEMBL1413877 0.85 KMT2A (0.58) RPA1ALDH1A1GRM5MEN1KMT2A
SCHEMBL4689569 0.85 RPA1 (0.48) RPA1ALDH1A1GRM5MEN1KMT2A
SCHEMBL2203114 0.84 RPA1 (0.51) RPA1ALDH1A1GRM5MAPTHTT
SCHEMBL14758758 0.84 PPP1CA (0.56) RPA1ALDH1A1GRM5MEN1KMT2A
SCHEMBL25139616 0.83 GRM5 (0.52) RPA1ALDH1A1GRM5MAPTKDM4E
SCHEMBL20647060 0.83 GRM5 (0.52) RPA1ALDH1A1GRM5MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085073-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS INC (US) 2026-03-26 — — US disclosed
EP-3710428-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-25 — — EP disclosed
US-20250346575-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-11-13 — — US disclosed
CN-120058672-A Halogenated pyridylcarboxylic acid ester derivative and application thereof 贵州医科大学 2025-05-30 — — CN disclosed
US-20250092014-A1 COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE METREA BIOSCIENCES INC (US) 2025-03-20 — — US disclosed
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-09-19 — — US disclosed
EP-4431505-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2024-09-18 — — EP disclosed
US-12065428-B2 Anti-viral compounds ALIGOS THERAPEUTICS, INC. (US) 2024-08-20 — — US disclosed
CN-118234721-A Isoindolinone derivative with glutarimide mother nucleus and application thereof 韩国化学研究院 2024-06-21 — — CN disclosed
US-11993729-B2 Chemical mechanical polishing composition BASF SE (DE) 2024-05-28 — — US disclosed
US-6884821-B1 Carboxylic acid derivatives and drugs containing the same EISAI CO., LTD. (JP) 2005-04-26 — — US disclosed
EP-1176140-B1 AMIDE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2004-12-29 — — EP disclosed
WO-2004018428-A1 ANTIBACTERIAL BENZOIC ACID DERIVATIVES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 — — WO disclosed
US-20030149043-A1 N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia PFIZER INC. 2003-08-07 — — US disclosed
US-6492401-B1 SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE PFIZER, INC. 2002-12-10 — — US disclosed
CN-1377336-A Carboxylic acid derivatives and drugs containing the same EISAI CO LTD (JP) 2002-10-30 — — CN disclosed
EP-1216980-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME Eisai Co., Ltd. (JP) 2002-06-26 — — EP disclosed
EP-1176140-A1 AMIDE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2002-01-30 — — EP disclosed
EP-1056729-A1 N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA Pfizer Products Inc. (US) 2000-12-06 — — EP disclosed
WO-1999043663-A1 N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA PFIZER PRODUCTS INC. (US) 1999-09-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12065428-B2 Anti-viral compounds EIF2AK2, ZC3HAV1, HAVCR2 RPA1 3078/4885ALDH1A1 2039/4885GRM5 4129/4885
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 RPA1 1718/4885ALDH1A1 3433/4885GRM5 1226/4885
US-20030149043-A1 N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia NHERF1, SLC28A1, TNNI3 RPA1 3034/4885ALDH1A1 642/4885GRM5 662/4885
US-20250092014-A1 COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE LPL, LIPA, PNLIP RPA1 3876/4885ALDH1A1 1201/4885GRM5 3994/4885
US-20260085073-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL3 RPA1 2303/4885ALDH1A1 2586/4885GRM5 4108/4885
US-20250346575-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF CRBN, IDH1, IDH2 RPA1 2641/4885ALDH1A1 849/4885GRM5 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback